Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

New York

New York

New York

New York

Great Neck

Lake Success

Rochester

Beaver Falls

Pittsburgh

Pittsburgh

Pittsburgh

Duncansville

Sayre

Philadelphia

Chevy Chase

Silver Spring

Lutherville

Annapolis

Norfolk

Rocky Mount

Charlotte

Charlotte

Wilmington

Wilmington

Jacksonville

Columbia

Conyers

Marietta

Atlanta

Atlanta

Atlanta

Savannah

Jacksonville

Jacksonville

Gainesville

Gainesville

Winter Park

Hollywood

North Miami Beach

Miami

Clearwater

Birmingham

Chattanooga

Chattanooga

Germantown

Picayune

Lexington

Beachwood

Cleveland

Warren

Cincinnati

Cincinnati

Cincinnati

Indianapolis

Columbus

Troy

Clive

Davenport

Milwaukee

Milwaukee

Milwaukee

Monroe

Plymouth

Arlington Heights

Rockford

Moline

St Louis

Kansas City

Overland Park

Topeka

Little Rock

Jonesboro

Tulsa

Tulsa

Austin

Wheat Ridge

Englewood

South Ogden

San Francisco

Roseville

Portland

Portland

Bellevue

Seattle

Vancouver

Spokane

Bridgeport

Hamden

Indianapolis

Boston

Boston

Burlington

Mexico

Lebanon

Egg Harbor

Glen Ridge

Manalapan